Abstract
Generic drugs account for 78 to 95% of drug products on the Russian pharmaceutical market and represent a common way of decreasing treatment cost. The main problem of generic drugs is a pharmaceutical quality and comparability between generic and original drug products, which has a significant impact on efficacy and safety of treatment. This paper addresses the issues concerning assessment of generic drugs and their correspondence to original drug product. The key definitions, such as pharmaceutical, pharmacokinetic (bioequivalence) and therapeutic equivalence, are considered. Results of comparative pharmaceutical quality analyses and equivalence studies using several antibiotics (ceftriaxone, cefotaxime, clarithromycin, azithromycin, meropenem) are provided. The problems of governmental regulation of quality control and submission for obtaining marketing authorization for generic drug products in Russia are discussed.
-
1.
Белоусов Ю.Б. Дженерики - мифы и реалии. Remedium 2003; (7-8):4-9.
-
2.
Division of Drug Management and Policies. Summary of Counterfeit Drug Database as of April 1999 [unpublished manuscript]. Geneva, Switzerland: World Health Organization; 1999.
-
3.
FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. 30th edition, 2010.
-
4.
EMEA, CPMP, Note for Guidance on the Investigation of Bioavailability and Bioequivalence, CPMP/EWP/ QWP/1401/98, London, July 2001.
-
5.
World Health Organization, 2010, WHO Expert Expert Committee on Specifications for Pharmaceutical Preparations: thirty-fourth report. WHO Technical Report Series No. 957, Geneva.
-
6.
Levy S.B., Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004; 10:S122-S129.
-
7.
Allen S. Prevention and control of infection in the ICU. Curr Anaesth Crit Care 2005; 16:191-9.
-
8.
Carlet J., Ben Ali A., Chalfine A. Epidemiology and control of antibiotic resistance in the intensive care unit. Curr Opin Infect Dis 2004; 17:309-16.
-
9.
Gusmro M.E.N., Dourado I., Fiaccone R.l., Salvador C. Nosocomial pneumonia in the intensive care unit of a brazilian university hospital: analysis of the time span from admission to disease onset. Am J Infect Control 2004; 32:209-14.
-
10.
Kollef M.H. Gram-negative bacterial resistance: evolving patterns and treatment paradigms. Clin Infect Dis 2005; 40 (suppl. 2):S85-S88.
-
11.
Kollef M.H., Fraser V.J. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134:298-314.
-
12.
Rosenthal V.D., Guzman S., Orellano P.W. Nosocomial infections in medical-surgical intensive care units in Argentina: attributable motality and lenght of stay. Am J Infect Control 2003; 31:291-5.
-
13.
Vincent J.L. Nosocomial infections in adult intensive care units. Lancet 2003; 361:2068-77.
-
14.
Wagenlehner F.M.E., Loibl E., Vogel H., Naber K.G. Incidence of nosocomial urinary tract infections on a surgical intensive care unit implications for management. Int J Antimicrob Agents 2006; 28:86-90.
-
15.
Lehr H.A., Brunner J., Rangoonwala R., Kirkpatrick C.J. Particulate matter contamination of intravenous antibiotics aggravates loss of functional capillary density in postischemic striated muscle. Am J Respir Crit Care Med 2002; 165:514-20.
-
16.
Wetterich U, Mutschler E. Quality of cefotaxime sodium preparations. Arzneimittelforschung 1995; 45:74-80.
-
17.
Wetterich U., et al. The 20th International Congress on Chemotherapy. Sydney, Australia, 1997, poster# 4297.
-
18.
Lambert P.A., Conway B.R. Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin. J Chemother 2003 Aug; 15:357-68.
-
19.
Nightingale C.H. A survey of the quality of generic clarithromycin products from 13 countries. Clin Drug Investig 2000; 19:293-305.
-
20.
Nightingale C.H. A survey of the quality of generic clarithromycin products from 18 countries. Clin Drug Investig 2005; 25:135-52.
-
21.
Панюшин Р. Оригинальные и дженериковые препараты: единство или борьба противоположностей? Фарм вестник 2003; (16):23.
-
22.
Никулин А.А., Цюман Ю.П., Мартинович А.А., Эйдельштейн М.В., Козлов Р.С. К вопросу о взаимозаменяемости внутривенных форм оригинальных и генерических препаратов: нужны ли сравнительные исследования? КМАХ 2010; 12:31-40.
-
23.
Доступно на http://www.minzdravsoc.ru/health/insurance/3
-
24.
Meos A., Gvozdev D. Comparative study of ciprofloxacin tablets registered in Estonia to those produced in Russian Federation. 6th World meeting on pharmaceutics, biopharmaceutics and pharmaceutical technology, 7-10 April 2008, Barcelona, Spain.